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Abstract: Tumor immune microenvironment has been shown to be important in predicting the tumor
progression and the outcome of treatments. This work aims to identify different immune patterns in
osteosarcoma and their clinical characteristics. We use the latest and best performing deconvolution
method, CIBERSORTx, to obtain the relative abundance of 22 immune cells. Then we cluster patients
based on their estimated immune abundance and study the characteristics of these clusters, along with
the relationship between immune infiltration and outcome of patients. We find that abundance of CD8
T cells, NK cells and M1 Macrophages have a positive association with prognosis, while abundance
of γδ T cells, Mast cells, M0 Macrophages and Dendritic cells have a negative association with
prognosis. Accordingly, the cluster with the lowest proportion of CD8 T cells, M1 Macrophages and
highest proportion of M0 Macrophages has the worst outcome among clusters. By grouping patients
with similar immune patterns, we are also able to suggest treatments that are specific to the tumor
microenvironment.
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1. Introduction
Osteosarcoma is the most common type of malignant bone tumors that appears most frequently in
children and young adults. It usually starts in the femur, the tibia and the humerus, and less commonly
the skull, the jaw or the pelvis [1]. There are some risk factor such as age, height, gender, and heritable
syndromes that predispose to for osteosarcoma, however, the cause of osteosarcomas is still not clear
[2].
Although neoadjuvant chemotherapy in treatment of osteosarcoma has shown better results,
overall survival of patients with metastasis still remains in low rate in the last three decades [3, 4].
Immunotherapy and targeted therapy have recently shown significant improvements for some
malignancies [5, 6]. Therefore, they are increasingly attractive treatment options for ostesarcoma
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patients. However, they are not effective for many patients and there is no evidence that proves the
effectiveness of a specific molecular target [7].
It has been shown in many studies that cancer cells and tumor infiltrating immune cells (TIICs)
have an important role in cancer progression and determination of malignant tumor types [8–10]. CD8
T cells, which is an important component of TIICs, has been found to associate with better clinical
outcomes and response to immunotherapy in many cancer types [11, 12]. Treatments that includes
the antitumor immunocompetence of innate immune cells, which includes NK cells and γδ T cells,
are found favorable for osteosarcoma tumors [13, 14]. These studies show the importance of finding
further biomarkers of tumor cells such as PD-1 and CTLA-4 and of tumor infiltrating immune cells
such as T cells and Macrophages to improve new treatment strategies and to choose the best treatment
strategy for osteosarcoma patients.
Several computational methods, alternative ways to immunohistochemistry and flow
cytometry [15], have been recently developed to derive tumor immune infiltrates using gene
expression profiles of bulk tumors. In this study, we use the latest popular deconvolution
method [16–20], CIBERSORTx [21], to investigate the immune patterns of tumors and analyze the
relationship between immune composition and clinical features of osteosarcoma patients.
There have been many other studies that utilize a deconvolution method to study the tumor
microenvironment of osteosarcoma. A number of them use the estimated immune infiltrations
calculated using CIBERSORT and/or immune scores calculated using ESTIMATE to find
immune-related genes that can predict the prognosis of osteosarcoma [22–25]. Another set of studies
find genes with prognostic values by applying Cox model on survival data or performing differentially
expressed genes analysis between two groups of interest, and then investigate the relationship
between these genes and estimated immune infiltrates [26–30]. Others study the association of
immune abundance with clinical information directly [24, 31–34]. Our work falls somewhat into the
third category.
Among the studies that directly investigate the relationship between immune infiltrations and
clinical information, three of them use TARGET data set [24, 31, 33], one uses data from
GSE21257 [32], and one uses data from GSE39058 [34].
Most of these studies use
CIBERSORT [24, 32–34], while the other uses ssGSEA and ImmuCellAI along with expression of
immune marker genes to get estimated abundance of immune cells [31]. Our study, on the other hand,
utilizes the latest and best performing version of deconvolution methods called CIBERSORTx
B-mode, and conducts our analyses on both TARGET data set and GSE21257 data set. We also
perform K-means clustering using the estimated immune abundance to study the clinical
characteristics of different immune patterns in osteosarcoma. Another study has used hierarchical
clustering on immune abundance, but they estimate immune abundance using ssGSEA and do not
focus on the clinical difference between clusters [35].
2. Materials and methods
2.1. Data collection and processing
The gene expression data sets in this study are obtained from 2 cohorts: TARGET (cohort 1) and
GSE21257 (cohort 2). Cohort 1 includes FPKM normalized RNA-seq data of 88 osetosarcoma
patients downloaded from the UCSC Xena web portal and their corresponding clinical data
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downloaded from the GDC data portal. Cohort 2 includes microarray data and corresponding clinical
features of 53 osteosarcoma samples, downloaded from GEO website. Cohort 2’s gene expression
data were previously normalized with robust spline normalization before being downloaded.
2.2. Relative abundance of immune cells
We calculate the relative frequencies of 22 immune cell types by applying CIBERSORTx [21] Bmode algorithm with immune signature matrix LM22 on gene expression data from both cohort 1 and
2. CIBERSORTx is the latest version of CIBERSORT (Cell type Identification By Estimating Relative
Subsets Of RNA Transcripts) [36], where batch correction method Combat has been introduced in the
algorithm to reduce the effect of cross-platform variation between gene expression data and signature
matrix. There are 2 modes of this algorithm: B-mode and S-mode, whose difference lies in the way
batch correction is applied in the algorithm. Our recent study has shown that CIBERSORTx B-mode
gives good estimates of immune abundance in both RNA-Seq and microarray data with the use of
LM22, and in fact outperforms CIBERSORT and other tumor deconvolution methods [16]. We obtain
estimated immune fractions by running the algorithm on their website with 100 permutations. Similar
to CIBERSORT, CIBERSORTx outputs a p-value for each deconvolved sample as an indicator of
confidence of the results. We use samples with p-value less than 0.05 for analyses in this study.
2.3. Identification of immune patterns in osteosarcoma
To calculate the abundance of each cell type, which has several subtypes with a small abundance,
we sum the proportions of their subtypes obtained from CIBERSORTx. The abundance of B cells is
the summation of naive and memory B cells; NK cell is the summation of resting and activated NK
cells; Mast cells is the summation of resting and activated Mast cells; Dendritic cells is the summation
of resting and activated Dendritic cells; and CD4 T cells is the summation of follicular helper T cells,
regulatory T cells, naive CD4 T cells, resting and activated memory CD4 T cells. We do not combine
subtypes of Macrophages because M1 and M2 Macrophages have very different functions and
Macrophages make up the majority of immune cells in osteosarcoma.
We then use K-means clustering to identify various immune patterns of osteosarcoma based on the
estimated immune cells’ abundance. The number of clusters in K-means is determined using elbow
method. A t-SNE visualization of the clusters is also included to see how well K-means algorithm
distinguishes between samples with different immune patterns.
2.4. Immune scores of osteosarcoma tumors
Immune scores of all samples in cohort 1 and 2 are computed from ESTIMATE algorithm [37]. In
order to do so, we run estimate package locally from R. We also divide all patients from both cohorts
into low immune score and high immune score group using the median immune score as cut-off to
study the relationship between immune score and survival outcome.
2.5. Statistical analysis
Chi-square test is used to analyze the relationship between categorical variables in this study. We
employ Mann-Whitney-Wilcoxon test to detect any significant difference between groups of
continuous variables, such as immune fractions, gene expression, age and immune score. Pearson
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correlation and corresponding p-value are used to study the correlation between different immune
infiltrates.
To investigate the impact of immune infiltrates on survival, for each immune cell, we split all
patients into high and low abundance group using the median value as cut-off and perform log-rank
test to find significant difference in survival between groups. Kaplan-Meier curves are also plotted to
visualize the differences between these groups.
All analyses in this study are conducted on all samples in both cohorts 1 and 2, except for metastasisfree survival analysis which is applied only on cohort 2 since cohort 1 does not include data on the time
of metastasis development. All statistical analyses and visualizations are carried out in Python.
3. Results
3.1. The most abundant immune cells in osteosarcoma are Macrophages and CD4 T cells
Results of CIBERSORTx B-mode on gene expression profiles of 141 osteosarcoma patients
(cohorts 1 and 2) demonstrates that M0 Macrophages is the most frequent immune cell in
osteosarcoma tumors with an average of 40% of total immune cells, followed by M2 Macrophages
and CD4 T cells (Figure 1B, C). Unsupervised hierarchical clustering of immune cell fractions shows
that most abundant cells tend to be clustered together, as is shown in Figure 1A, where M0 and M2
Macrophages are clustered together and then grouped with CD4 T cells and other immune cells. In
addition, the most frequent cells also have the highest variation in abundance across osteosarcoma
tumors (Figure 1B).
3.2. Correlation between immune infiltrates in osteosarcoma
According to the CIBERSORTx B-mode results, abundance of CD8 T cells is negatively
correlated with M0 Macrophages and positively correlated with M1 Macrophages with Pearson
correlation coefficients of −0.62 and 0.55, with p-values of 4.8e−16 and 1.1e−12, respectively (Figure
1E). The proportion of γδ T cells is also significantly negatively correlated with CD4 T cells and NK
cells (Pearson coefficients of −0.6 and −0.62, with p-values of 4.3e−15 and 1.8e−16). Interestingly,
frequencies of M0 and M1 Macrophages exhibit a negative correlation of −0.61 with p-value 1e−15.
3.3. There are 3 immune patterns of osteosarcoma
K-means clustering of immune cell proportions in osteosarcoma tumors indicates the existence of
three distinct immune classes (Figure 1D), namely: Cluster 1, which has the highest proportions of
CD8 T cells, γδ T cells, M1 Macrophages, Mast cells and Plasma cells and the lowest proportion of
M0 Macrophages; Cluster 2, in which the percentage of M0 Macrophages is the highest; and Cluster
3, which has the highest percentage of M2 Macrophages. A t-SNE plot of immune cell proportions
suggests that K-means clustering algorithm successfully separates osteosarcoma patients with different
immune patterns (Figure 1G).
3.4. Cluster 2 has the worst survival outcome among all clusters
While there is no significant difference in gender, age and proportion of metastasis at diagnosis
between clusters (Figure 2A, B, F), we observe some differences in survival outcomes among clusters.
Mathematical Biosciences and Engineering

Volume 18, Issue 2, 1879–1897.

1883

!

"

#

$

%

&

'

Figure 1. Immune pattern of osteosarcoma. Sub-figure A shows the hierarchical clustering
of estimated immune cells’ infiltration. Sub-figure B and C display the boxplot and stacked
barchart of these immune cells’ fractions. Sub-figures D shows the average frequencies of
immune cells in 3 clusters obtained from K-means clustering. Sub-figure E indicates the
correlation map of immune cell frequencies. Sub-figure F displays the boxplot of ESTIMATE
immune scores in 3 clusters, with asterisks indicating significant difference from MannWhitney-Wilcoxon test (ns: no significance, *: 0.01 < p ≤ 0.05, **: 0.001 < p ≤ 0.01,
***: 0.0001 < p ≤ 0.001, ****: p ≤ 0.0001). Sub-figure G shows t-SNE plot of estimated
immune abundance, color coded by cluster.
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Kaplan-Meier curves indicate that cluster 2 has the worst survival probability throughout time out
of all clusters (Figure 2G). In addition, cluster 2, along with cluster 1, has higher percentage of dead
patients at the last time of follow up than cluster 3 (Figure 2C). Interestingly, cluster 2 also has the
lowest immune scores compared to other clusters (Figure 1F).
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Figure 2. Clinical characteristics of clusters and relationship between clinical features of
osteosarcoma. Sub-figure A-E show percentage of patients by gender (A), metastasis at
diagnosis (B), vital status at the last time of follow-up (C), Huvos grade (D), primary tumor
location (E), in the 3 clusters. Sub-figure F shows a boxplot of patients’ age at diagnosis in
each cluster. Sub-figure G displays Kaplan-Meier curves of overall survival across 3 clusters.
Sub-figures H-K shows the association between clinical features, H: percentage of alive and
dead patients by metastasis at diagnosis, I: percentage of alive and dead patients by Huvos
grade, J: percentage of low and high Huvos grade by tumor location, K: boxplot of age at
diagnosis by gender, with asterisks indicating significant difference from Mann-WhitneyWilcoxon test (ns: no significance, *: 0.01 < p ≤ 0.05, **: 0.001 < p ≤ 0.01, ***:
0.0001 < p ≤ 0.001, ****: p ≤ 0.0001).
Cluster 3 appears to have the best outcome among clusters. It has the lowest percentage of dead
patients at the last time of follow up among all clusters (Figure 2C), and better survival rate than cluster
2 over time (Figure 2G) with p-value 0.07 from the log-rank test.
Cluster 1, which has the highest amount of CD8 T cells, γδ T cells, M1 Macrophages and Mast
cells, has slightly better overall survival time than cluster 2 (p = 0.16, Figure 2G). However, cluster
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1 seems to have worse outcome than cluster 3 due to its higher percentage of dead patients at the last
time of follow up (Figure 2C). It is worth noting that there is no significant difference in the survival
rate between cluster 1 and 3 according to the log-rank test (p = 0.5, Figure 2G).
3.5. There is a relationship between certain clinical features of osteosarcoma
The Chi-square test and Mann-Whitney-Wilcoxon test show a relationship between metastasis at
diagnosis and vital status (p = 0.001, Figure 2H), Huvos grade, which is a grading system to evaluate
a patient’s response to chemotherapy based on the percentage of necrosis in the tumor after treatment,
and vital status (p = 0.036, Figure 2I), and between gender and age (p = 2.3e−4, Figure 2K) where
male patients are older on average. We observe that patients with metastasis at diagnosis have much
higher percentage of being dead at the last time of follow up than patients without metastasis (Figure
2H). This makes perfect sense since metastases have been known to associate with late stages of tumor
and poor prognosis in many cancers. The other clinical feature with a relation to vital status is Huvos
grade. Higher percentage of patients with high Huvos grade (3-4) are alive at the last time of follow
up than patients with low Huvos grade (1-2) (Figure 2I), which is reasonable since a high Huvos grade
means good response to chemotherapy. Figure 2J suggests that primary osteosarcoma tumors in the
arm respond more poorly to chemotherapy than leg tumors, as illustrated by the high proportion of
Huvos grade 1-2 in arm tumors. However, it is important to note that primary osteosarcoma tumors
happen more often in the leg than in the arm (Figure 2E), and the observation in Figure 2J is based on
a small number of arm tumor samples (n = 8), thus the relationship between tumor location and Huvos
grade is not considered significant by the Chi-square test (p = 0.18).
3.6. Immune score does not relate to vital status directly, but does relate to survival probability over
time
Figure 3D indicates no clear difference in immune score between alive and dead patients at the
last time of follow up. However, Kaplan-Meier curves of high and low immune score with a median
cut-off reveal that the high immune score group has a better outcome (Figure 3E). The log rank test
supports this observation with a p-value of 0.03. Thus, higher immune score is associated with better
survival probability throughout time. This is consistent with the observation of outcome in the clusters.
Cluster 2 has significantly lower immune score than cluster 1 and 3 (Figure 1F), with p-values of 5e−9
and 2.1e−5 from Mann-Whitney-Wilcoxon test, and accordingly worse overall survival probability
over time than cluster 1 and 3 (Figure 2G). Cluster 1, with the highest average immune score among
clusters (Figure 1F), even though has about the same proportion of dead patients at the last time of
follow up as cluster 2 (Figure 2C), shows better survival time than cluster 2 (Figure 2G).
3.7. Relationship between immune infiltrates and survival outcome in osteosarcoma
The Mann-Whitney-Wilcoxon test shows that there is a significant difference in the level of γδ T
cells and Mast cells between alive and dead patients at the last time of follow up, with p-values of
0.045 and 0.022, where dead patients are associated with higher percentages of γδ T cells and Mast
cells than alive patients (Figure 3A). Dendritic cells, NK cells and CD8 T cells also seem to associate
with survival status in osteosarcoma. We observe higher level of NK cells (p = 0.063), CD8 T cells (p
= 0.1) and lower level of Dendritic cells (p = 0.052) in alive patients than in dead patients (Figure 3A).
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Figure 3. Relationship of immune infiltrations with survival in osteosarcoma. Sub-figure
A displays violin plots of fractions of γδ T cells, Mast cells, Dendritic cells, NK cells, CD8
T cells between alive and dead patients. Sub-figures B, C, E, F show Kaplan-Meier curves
of overall survival between 2 groups, B: high vs low Dendritic cells, C: high vs low M0
Macrophages, E: high vs low ESTIMATE immune score, F: high vs low CD8 T cells. Subfigure D shows a boxplot of ESTIMATE immune scores between alive and dead patients.
Note: asterisks indicate significant difference from Mann-Whitney-Wilcoxon test (ns: no
significance, *: 0.01 < p ≤ 0.05, **: 0.001 < p ≤ 0.01, ***: 0.0001 < p ≤ 0.001, ****:
p ≤ 0.0001).

Kaplan-Meier curves (Figure 3B, C, F) and the log rank test indicate an association between survival
outcomes and levels of Dendritic cells, M0 Macrophages and CD8 T cells, with a p-value of 0.01, 0.04
and 0.04, respectively. Low Dendritic cells, low M0 Macrophages and high CD8 T cells are associated
with better survival probability over time in osteosarcoma patients. This is again consistent with the
outcome of the clusters where cluster 2, with the highest level of M0 Macrophages and lowest CD8 T
cells, has the worst overall survival.
Overall, we found that γδ T cells, Mast cells, Dendritic cells, M0 Macrophages, NK cells and CD8
T cells have a relationship with the survival of osteosarcoma patients.
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3.8. Association of immune infiltrates with other clinical features
We see no significant relationship between age or metastasis at diagnosis and the frequencies of
immune cells. However, we notice an association of M1 Macrophages and CD8 T cells’ frequencies
to metastasis-free survival. High levels of M1 Macrophages and CD8 T cells are associated with better
metastasis-free survival probability across time in osteosarcoma (Figure 4A, B), with p-values of 0.05
and 0.08 from the log-rank test, respectively. This means that patients with more M1 Macrophages
and CD8 T cells are less likely to develop metastasis or die at any given time than patients with low
percentage of these cells.
A relationship between some immune infiltrates and other clinical features of osteosarcoma has also
been observed. Higher level of NK cells is associated with good response to chemotherapy (p = 0.035,
Figure 4C). Patients with arm tumors have higher percentage of Plasma cells and Dendritic cells than
patients with leg tumors (Figure 4D, E), with p-values of 0.046 and 0.033. Lastly, female patients are
shown to have higher frequency of Neutrophils (Figure 4F), with p-value 0.0016.

!

"

$

%

#

&

Figure 4. Association of immune infiltrations and other clinical features. Sub-figures A and
B show Kaplan-Meier curves of metastasis-free-survival in cohort 1 between 2 groups, A:
high vs low M1 Macrophages, B: high vs low CD8 T cells. Sub-figures C-F are boxplots to
indicate relationship of immune infiltrates with Huvos grade (C), primary tumor location (D
and E), and gender (F). Note: asterisks indicate significant difference from Mann-WhitneyWilcoxon test (ns: no significance, *: 0.01 < p ≤ 0.05, **: 0.001 < p ≤ 0.01, ***:
0.0001 < p ≤ 0.001, ****: p ≤ 0.0001).
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3.9. Expression level of genes encoding PD-1, INF-γ, CTLA4, TNF, IL1-β, IGF1, IL-6 and RUNX2
are significantly different for some clusters
We use the gene expression values for some important proteins, and we analyze gene expression
value of the proteins separately for cohort 1 and 2 because they have different data types: RNA-Seq
and microarray, respectively.
Programmed cell death protein 1 (PD-1) is a type of protein on T cells and cancer cells use it to
bind with PD-1 ligand (PD-L1) and PD-2 ligand (PD-L2) to escape cell death by immune cells. There
is a high correlation between PDCD1 gene, which encodes PD-1 protein, and CD8 T cells in both data
sets with correlation coefficient of 0.70 and 0.77, respectively, and p-values less than 0.05 (Figure 6).
As a result of this correlation, PDCD1 is the highest in cluster 1 (Figure 5A1, B1). Cluster 1 also
has the highest expression of CTLA4 gene (Figure 5A3, B3) that encodes Cytotoxic T-Lymphocyte
Associated Protein 4 (CTLA4), which is a member of immunoglobulin superfamily and has been found
to significantly associate with the risk of osteosarcoma [38,39]. Moreover, we see that gene expression
value of CTLA4 is significantly correlated with CD8 T cells in osteosarcoma tumors (Figure 6).
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Figure 5. Gene expression values of important proteins in the clusters. Sub-figures (A1–A7)
and (B1–B7) show the gene expression values that come from cohort 1 and cohort 2 data sets,
respectively.
Interferon γ (INF-γ), encoded by IFNG gene, has antiviral, immunoregulatory, and anti-tumor
properties in the immune system and is secreted by mostly T cells and NK cells [40]. Importantly,
CD8 T cells frequency and PDCD1 gene expression are significantly correlated with IFNG gene
Mathematical Biosciences and Engineering

Volume 18, Issue 2, 1879–1897.

1889

expression so that cluster 1 has the highest level of IFNG compared the other clusters (Figure 5A2,
B2). Beside these, we do not see any significant correlation between expression levels of CD274 and
PDCD1LG2 genes, that encodes PD-L1 and PD-L2 respectively, with the expression levels of
PDCD1 and IFNG, and the percentage of CD8 T cells in osteosarcoma tumors (Figure 6).
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Figure 6. Correlation and distribution of important proteins in the clusters. Sub-figures A
and B represent the cohort 1 and cohort 2 data sets respectively.

Tumor necrosis factor (TNF) is a cytokine that is mainly produced by Macrophages and has crucial
roles in tumor development and tumor progression inducing apoptosis, necrosis, angiogenesis, immune
cell activation, differentiation, and cell migration [41]. We notice that cluster 2 has the lowest TNF gene
expression among clusters, while cluster 1 and 3 have roughly similar average expression of this gene
(Figure 5A4, B4). In addition, we analyze gene IL1B that encodes cytokin protein Interleukin-1 beta
(IL-1β), which is produced by activated Macrophages [42], and see that IL1B gene expression is the
lowest in cluster 2 and the highest in cluster 3 (Figure 5A6, B6).
Beside these, Insulin-like growth factor 1 (IGF-1) is a hormone that has important function in the
development and function of many tissues and it has been used as a diagnostic marker for osteosarcoma
[43, 44]. Similar to TNF and IL1B genes expression, cluster 2 has the lowest amount of IGF1 among
other clusters (Figure 5A5, B5). Furthermore, we examine RUNX2 oncogene that is associated with
amplifications and it has been found to correlate to poor response to chemotherapy in osteosarcoma
[45, 46]. In our analysis, cluster 1 has the lowest amount of RUNX2 gene and cluster 2 and 3 show
almost similar expression of RUNX2 gene (Figure 5A7, B7).
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4. Discussion
The findings from analyses using estimated immune infiltrations in osteosarcoma have varied
among studies, perhaps due to the small number of osteosarcoma tumors with available gene
expression data in the literature. In this study, we find that infiltration of CD8 T cells, NK cells and
M1 Macrophages have a positive association with prognosis, while infiltration of γδ T cells, Mast
cells, M0 Macrophages and Dendritic cells have a negative association with prognosis. Yu et al. [24]
also illustrates that high level of CD8 T cells is a good prognosis in their survival analysis, and results
from [26] and [28] indirectly suggest the positive prognostic value of CD8 T cells. Tang et al. [26]
reports that CD8 T cells infiltration has a positive correlation with CXCR3 expression which is related
to good prognosis. Khader et al. [28] shows that low-risk patients have high level of CD8 T cells and
NK cells, which supports with our conclusion on these cells. In agreement with our findings on
prognostic value of M1 Macrophages, Song et al [31] demonstrates that high level of M1
Macrophages is associated with good prognosis, while Zhang et al. [22] and Tang et al. [26] imply the
same from their results. Our conclusion about M0 Macrophages aligns with the results from [22]
and [26], but contradicts with the finding from [34] that abundance level of M0 Macrophages is
positively correlated with survival.
The observable difference in outcomes between clusters are likely due to the relationship between
immune infiltrates and prognosis in osteosarcoma, because we cluster the patients based on their
immune composition. Our results indicate that cluster 2 has the worst outcome, while cluster 3 seems
to have the best outcome among clusters. The main difference in immune composition between these
two clusters is that cluster 2 has much higher percentage of M0 Macrophages, and lower percentage
of CD8 T cells and M1 Macrophages than cluster 3. In general, we found that high levels of CD8 T
cells and M1 Macrophages are associated with good prognosis, while a high level of M0
Macrophages correlates with poor prognosis in osteosarcoma. These results make sense because CD8
T cells are known to kill cancer cells directly [47, 48] and M1 Macrophages exhibit anti-tumor effects
by producing cytokines that inhibit osteosarcoma growth [49]. These facts could also explain the
observed differences between the outcomes of patients in clusters 2 and 3. Meanwhile, cluster 1 has
worse outcome than cluster 3, but better outcome than cluster 2. This could be due to the fact that
cluster 1 has both high level of immune cells associated with good prognosis such as CD8 T cells and
M1 Macrophages, and high level of immune cells associated with poor prognosis according to our
results such as γδ T cells and Mast cells. A high infiltration of mast cells has been associated with
poor prognosis, low survival and increased metastasis in many cancers [50], while γδ T cells show
dual effects on cancer growth [51]. Both mast cells and γδ T cells promote tumor development by
supporting angiogenesis through angiogenic factors production [50, 51]. Mast cells also produce
proteases, which lead to extracellular matrix degradation and tissue remodeling, and thus promote
tumor growth [50]. γδ T cells have been reported to secrete TGF-β [51], which is a pro-tumor
cytokine in osteosarcoma [52–54]. Overall, the clinical outcomes of the clusters are consistent with
our findings and biological knowledge on prognostic values of immune cells in osteosarcoma.
On the other hand, we did not observe any difference in age or metastasis at diagnosis between
clusters. This can be explained by the lack of correlation between immune infiltrates and these clinical
variables, which suggests that the immune composition of the primary tumor has no effect on age or
metastasis status at diagnosis.
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Immune checkpoints have an important role in the immune system to prevent autoimmune
diseases, but unfortunately they can allow immune tolerance against tumors. PD-1 and CTLA-4 are
the main checkpoints that tumor cells use to block immune system [55–57]. Blocking PD-1 pathway
has improved oncological survival of several patients with metastatic cancers, including melanoma,
renal cell carcinoma, and colon cancer [58, 59]. Also, targeting CTLA-4 in patients with metastatic
melanomas demonstrates significant development about overall survival [60].
It has been reported that osteosarcoma patients treated with an anti PD-1 drug, Pembrolizumab,
show some improvement in disease progression [61]. Combination of PD-1 and CTLA-4 blockade
therapy in bone sarcoma have shown better response compared to single checkpoint inhibitor therapy
[62]. Note, patients in cluster 1 have the highest expression levels of IFNG, PDCD1 and CTLA-4
that are significantly correlated with CD8 T cells (Figures 5 and 6), and it has been shown that INF-γ
increases the CD8 T cells expansion [63]. Thus, patients in cluster 1 might respond well to combination
of PD-1 and CTLA-4 blockade therapies.
It has been suggested in several studies that bacteria are able to activate anti-tumor immune
responses [64, 65]. In a study with combination of Bacillus Calmette-Guerin (BCG) injection and
tumor vaccine, 18% of the patients remained alive and disease-free and it has been reported that
bacterial vaccine caused increased level of immunoregulatory cytokines such as TNF-α, IFN-γ, and
IL1-β that might be involved in inducing tumor regression [66]. As a result, bacterial vaccine and
inactivated tumor cells injection can be thought of as a treatment that activates anti-tumor immune
responses [47]. In our results, cluster 2 has the lowest amount of gene expression level of
immunoregulatory cytokines TNF-α, IFN-γ, and IL1-β (Figure 5) so that tumors in this cluster might
be treated with bacterial vaccine. Otherwise, targeting RUNX2 oncogene with chemotherapy is
suggested as a new therapeutic approach to osteosarcoma patients in recent studies [46, 67] and
cluster 2 has the highest amount of RUNX2 gene expression values compared to other clusters
(Figure 5A7–B7) so with the help of further studies, tumors similar to those in cluster 2 also might be
good candidates to treat with targeting RUNX2 in conjunction to standard chemotherapy.
Targeting tumor associated macrophages (TAM) is another alternative treatment method for
osteosarcoma tumors and treatments that suppress M2 Macrophages phenotype or block the
polarization of M1 Macrophages to M2 Macrophages have shown positive results in several
studies [68–71]. Thus, tumors in cluster 3, which has the highest amount of M2 macrophages (Figure
1D) can be treated with targeting TAMs.
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Appendix
A.1. CIBERSORTx B-mode algorithm
CIBERSORTx is the latest version of CIBERSORT, which has been the most popular deconvolution
method up until now. Both algorithms are based on the following model:
y = Xβ
where y is the vector of gene expression values of the bulk tumor, called mixture data, X is the signature
matrix where each column is a vector of gene expression values of a cell type, and β is the vector of
estimated cell fractions.
CIBERSORT solves for β using a machine learning technique called nu-Support Vector Machine
(ν-SVR). Specifically, CIBERSORT finds β by minimizing the objective function:


N
X


1
1

(ξi + ξi∗ )
kβk2 + C ν +
2
N i=1
s.t. yi − ŷi ≤  + ξi and ŷi − yi ≤  + ξi∗ and ξi , ξi∗ ≥ 0.
Here  is the margin of error, ν is a model hyperparameter between 0 and 1, ŷi is the predicted value
of yi , and (ξi + ξi∗ ) is the absolute error of ŷi that lie outside margin of error  from yi . By minimizing
this objective function, CIBERSORT finds estimated fractions β̂ that result in the smallest absolute
error between observed and predicted mixture data (y and ŷ) where a margin of error  is tolerated.
After this optimization step, all negative coefficients in the estimated β̂ are set to 0 and the coefficients
are normalized to sum to 1 because β̂ represents cell fractions.
CIBERSORTx extends CIBERSORT by adding batch correction to adjust the potential
cross-platform variations between mixture data y and signature matrix X. The algorithm of
CIBERSORTx B-mode works as follows:
1. Given signature matrix X and mixture data y, obtain estimated cell fractions β̂ from CIBERSORT
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2. Compute estimated mixture data ŷ as ŷ = X β̂
3. Use Combat, a well-known batch correction method, to adjust the technical variations between y
and ŷ, outputing adjusted mixture data yad j
4. Obtain final estimated cell fractions from X and yad j using CIBERSORT
A.2. ESTIMATE algorithm for Immune Score
Given an immune gene set, which is a set of genes associated with the quantity of immune
infiltrations, ESTIMATE uses single sample gene set enrichment analysis (ssGSEA) to compute the
Immune Score from gene expression data of bulk tumor. A high Immune Score represents a high level
of infiltrating immune cells in the tumor tissue. ssGSEA algorithm in ESTIMATE works as follows:
1. Order gene expression data of bulk tumor from highest to lowest and replace gene expression
values with their ranks
2. For each gene i, compute the following:
X
|r j |α
PGw (G, y, i) =

r j ∈G, j≤i

X

|r j |α

,

r j ∈G

PNG (G, y, i) =

1
,
(N − NG )
r <G, j≤i
X

j

where G is the given immune gene set which has NG genes, y is the gene expression data of bulk
tumor which has N genes, r j is the rank of gene j and α is a hyperparameter between 0 and 1.
3. The Immune Score of sample y given immune gene set G is:
IS (G, y) =

N
X



PGw (G, y, i) − PNG (G, y, i) .

i=1

A.3. K-means clustering algorithm
Given a number of clusters k, K-means clustering works as follows:
1. Randomly choose k data points as centroids
2. Assign each data point to its closest centroid, resulting in k clusters based on k centroids
3. Compute a new centroid for each cluster by taking average of data points that belong to that
cluster
4. Repeat step 2 and 3 until the centroids no longer change
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